NCT03984110: An overdue trial by Texas Retina Associates
This trial is overdue. It was due to report 1 year, 9 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03984110 |
|---|---|
| Title | The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 11, 2019 |
| Completion date | Oct. 27, 2022 |
| Required reporting date | Oct. 27, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | 655 |